Pyxis Oncology, Inc.(PYXS)

$3.75—

Chart

Pyxis Oncology, Inc.(PYXS)

NASDAQ

$3.75—

Chart Studio

PYXS(PYXS)

PYXS

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.27

Nov 2, 2026 · Reports before open

Analyst Sentiment

Wall St. Consensus

Buy

10 analysts·Moderate coverage

Score

8 Buy (80%)2 Hold (20%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

880%

Hold

220%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$6.00

+58.3%

Consensus

$6.50

+71.5%

Bull

$7.00

+84.7%

12-Month Target Range10 analysts

$6.00$6.50$7.00

Current $3.79Consensus

Current Price

$3.79

Upside to Consensus

$2.71

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+14185.71%

EPS—

FY2028

Rev+405.15%

EPS—

FY2029

Rev+170.83%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$21,875	$3M	$16M	$43M	$112M
Low	$21,875	$3M	$16M	$43M	$112M
High	$21,875	$3M	$16M	$43M	$112M
EBITDA Avg	$-73M	$-69M	$-59M	$-61M	$-38M
Low	$-82M	$-95M	$-97M	$-61M	$-38M
High	$-64M	$-44M	$-22M	$-61M	$-38M
EBIT Avg	$-76M	$-72M	$-61M	$-63M	$-40M
Low	$-85M	$-98M	$-99M	$-63M	$-40M
High	$-68M	$-47M	$-24M	$-63M	$-40M
Net Income Avg	$-76M	$-72M	$-61M	$-63M	$-40M
Low	$-85M	$-98M	$-99M	$-63M	$-40M
High	$-68M	$-47M	$-24M	$-63M	$-40M
EPS Avg	$-1.22	$-1.13	$-1.10	$-1.02	$-0.64
Low	$-1.37	$-1.57	$-1.59	$-1.02	$-0.64
High	$-1.09	$-0.75	$-0.38	$-1.02	$-0.64
Analysts (Rev / EPS)	9 / 6	9 / 6	9 / 7	4 / 2	4 / 4

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	—	$25,000	—	—	$3M	$9M	—	—
Low	—	$25,000	—	—	$3M	$9M	—	—
High	—	$25,000	—	—	$3M	$9M	—	—
EBITDA Avg	—	$-17M	—	—	$-17M	$-16M	—	—
Low	—	$-20M	—	—	$-17M	$-16M	—	—
High	—	$-13M	—	—	$-17M	$-16M	—	—
EBIT Avg	—	$-17M	—	—	$-17M	$-17M	—	—
Low	—	$-20M	—	—	$-17M	$-17M	—	—
High	—	$-13M	—	—	$-17M	$-17M	—	—
Net Income Avg	$-18M	$-17M	$-15M	$-16M	$-17M	$-17M	$-20M	$-20M
Low	$-20M	$-20M	$-15M	$-16M	$-17M	$-17M	$-20M	$-20M
High	$-16M	$-13M	$-15M	$-16M	$-17M	$-17M	$-20M	$-20M
EPS Avg	$-0.28	$-0.26	$-0.24	$-0.25	$-0.26	$-0.26	$-0.31	$-0.31
Low	$-0.32	$-0.31	$-0.24	$-0.25	$-0.26	$-0.26	$-0.31	$-0.31
High	$-0.26	$-0.20	$-0.24	$-0.25	$-0.26	$-0.26	$-0.31	$-0.31
Analysts (Rev / EPS)	— / 6	9 / 6	— / 2	— / 2	4 / 2	7 / 2	— / 5	— / 5

Earnings Surprises

Recent Analyst Actions

Jul 2, 2026Leerink Partners

Pyxis Oncology Inc. (PYXS) PT Lowered to $7 at Leerink

Target:$7.00

+145.6%from $2.85

May 5, 2026Wedbush

Wedbush bullish on Pyxis Oncology, initiates with an Outperform

Target:$6.00

+240.9%from $1.76

Dec 18, 2025RBC Capital

Pyxis Oncology Inc. (PYXS) PT Lowered to $5 at RBC Capital

Target:$5.00

+189.0%from $1.73

Nov 24, 2025Stephens

Pyxis Oncology price target raised to $8 from $5 at Stephens

Target:$8.00

+66.7%from $4.80

Nov 4, 2025Guggenheim

Pyxis Oncology Inc. (PYXS) PT Raised to $7 at Guggenheim

Target:$7.00

+83.7%from $3.81

Sep 4, 2025Guggenheim

Pyxis Oncology initiated with a Buy at Guggenheim

Target:$5.00

+210.6%from $1.61

Aug 16, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Pyxis Oncology Inc. (PYXS)

Target:$7.00

+98.9%from $3.52

Aug 7, 2024Stifel Nicolaus

Pyxis Oncology initiated with a Buy at Stifel

Target:$10.00

+219.5%from $3.13

May 7, 2024Jefferies

Jefferies Assumes Pyxis Oncology Inc. (PYXS) at Buy

Target:$10.00

+132.0%from $4.31

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance